Journal Mobile Options
Table of Contents
Vol. 29, No. 3, 2011
Issue release date: April 2011
Fetal Diagn Ther 2011;29:229–232
(DOI:10.1159/000322041)

Accumulation of Fetal IgG in Immunoglobulin Injection into the Fetal Abdominal Cavity Is Proven

Yoshida M. · Matsuda H. · Hasegawa Y. · Yoshinaga Y. · Asai K. · Kawashima A. · Furuya K.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: There have been a number of studies on immunoglobulin injection into fetuses or mothers during pregnancy for the treatment of congenital cytomegalovirus infection. However, no study has examined the effect of injected immunoglobulin on fetal hemodynamics. In this study, we examined the effect of immunoglobulin injection on fetal hemodynamics by retrospectively measuring the concentrations of several IgG subclasses in stored umbilical cord blood sera collected during fetal therapy. Methods: Five patients who underwent immunoglobulin injection into the fetal abdominal cavity (IFAC) as a fetal therapy during pregnancy were included in this study. Frozen-stored umbilical venous blood samples collected from these patients during IFAC were measured for serum concentrations of each IgG subclass. Results: The largest change was observed in the IgG2 concentration, with a mean increase of 221% following IFAC. The IgG4 concentration also showed a mean increase of 63%. In contrast, the concentration of IgG1, which has the strongest physiological activity of all IgG subclasses examined, only exhibited an overall mean increase of 1.4%. Conclusion: Our results confirmed that immunoglobulins are incorporated into the fetal circulation following IFAC.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Negishi H, Yamada H, Hirayama E, et al: Intraperitoneal administration of cytomegalovirus hyperimmunoglobulin to the cytomegalovirus-infected fetus. J Perinatol 1998;18:466–469.
  2. Matsuda H, Kawakami Y, Furuya K, et al: Intrauterine therapy for a cytomegalovirus-infected symptomatic fetus. BJOG 2004;111:756–757.
  3. Matsuda H, Sakaguchi K, Shibasaki T, et al: Intrauterine therapy for parvovirus B19-infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med 2005;33:561–563.
  4. Nigro G, Adler SP, La Torre R, et al: Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005;353:1350–1362.
  5. Adler SP, Nigro G: Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol 2009;46(suppl 4):S54–S57.
  6. Luppi P: How immune mechanisms are affected by pregnancy. Vaccine 2003;21:3352–3357.
  7. Simister NE: Placental transport of immunoglobulin G. Vaccine 2003;21:3365–3369.
  8. Gitlin D, Boesman M: Serum α-fetoprotein, albumin, and γ-globulin in the human conceptus. J Clin Invest 1966;45:1826–1838.
  9. Gitlin D, Biasucci A: Developent of γG, γA, γM, βIC-βIA, C1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, heptoglobin, fibrinogen, plasminogen, α1-antitrypsin, orosomucoid, β-lipoprotein, α2-macroglobulin, and prealbumin in the human conceptus. J Clin Invest 1969;48:1433–1446.
  10. Israel EJ, Simister N, Freiberg E, et al: Immunoglobulin G binding sites on the foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology 1993;79:77–81.
  11. Cederqvist LL, Ewool LC, Bonsnes RW, et al: Detectability and pattern of immunoglobulins in normal amniotic fluid throughout gestation. Am J Obstet Gynecol 1978;130:220–224.
  12. Malek A: Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 2003;21:3362–3364.
  13. Garty BZ, Ludomirsky A, Danon YL, et al: Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994;1:667–669.
  14. Shrim A, Garcia-Bournissen F, Maxwell C, et al: Favorable pregnancy outcome following trastuzumab (Herceptin) use during pregnancy: case report and updated literature review. Reprod Toxicol 2007;23:611–613.
  15. Roopenian DC, Akilesh S: FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715–725.
  16. Burns JC, Capparelli EV, Brown JA, et al: Intravenous γ-globulin and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144–1148.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00